Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Charu AggarwalRoger B CohenMatthew P MorrowKimberly A KraynyakAlbert J SylvesterDawson M KnoblockJoshua M BaumlGregory S WeinsteinAlexander LinJean BoyerLindsay SakataSophie TanAubrey AntonKelsie DickersonDrishty MangroliaRussell VangMichael DallasSandra OyolaSusan DuffMark EsserRakesh KumarDavid WeinerIldiko CsikiMark L BagarazziPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
These data demonstrate that MEDI0457 can generate durable HPV16/18 antigen-specific peripheral and tumor immune responses. This approach may be used as a complementary strategy to PD-1/PD-L1 inhibition in HPV-associated HNSCCa to improve therapeutic outcomes.